< back to headlines

September 25, 2006

Aegerion Pharmaceuticals Inc. Hires Vice President of Business Development

Move is designed to continue building the pipeline and create strategic partnerships both in the US and overseas

Bridgewater, NJ (September 25, 2006)  Aegerion Pharmaceuticals Inc. announced that Thomas G. Burger has joined the company as Vice President, Business Development. Mr. Burger brings over 20 years of Business Development in emerging growth companies and International Investment Banking (Mergers & Acquisitions). Most recently, Tom was Vice President, Business Development at Daiichi Pharmaceuticals and spent nearly 8 years as Head of Corporate Development at Genta, Inc. While at Genta, Tom closed the second largest single-product license & co-promotion transaction in the history of the pharmaceutical business with Aventis Pharmaceuticals in 2002.

“We are extremely pleased to have been able to recruit Tom Burger to Aegerion. He brings a wealth of experience and contacts both here in the US and in Japan where has both studied and worked for nearly 10 years. His proven ability to contribute to the growth of early stage pharmaceutical companies and close significant transactions will be very valuable to Aegerion as we begin executing our growth strategies”, sand Jerry Wisler, President and CEO of Aegerion Pharmaceuticals.

“The chance to join an early stage company with late stage, large market products, is very attractive to any Business Development professional. The ability to work with a talented team to build our presence in cholesterol management arena represents an exciting opportunity. In addition, the large market need and the role of MTP Inhibitors which the Company is developing offers a strong position from which to build.”, said Mr. Burger.

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company focused on the development and commercialization of promising pharmaceuticals to treat cardiovascular and metabolic disease. The Company's initial focus will be on hyperlipidemia. Its most advanced products have demonstrated significant LDL lowering activity in human trials and are currently in Phase II testing.

Contact

Kate Childress, Vox Medica Health-care Public Relations Group
(t) 215-238-8500 ext 1107
(e) kchildress@voxmedica.com

###